| abstract |
The invention discloses a metal-organic composite nano-medicine, comprising heterostructured metal-based nanoparticles treated with a first surface modifier and a cross-linking agent in sequence, and a drug component compound treated with a second surface modifier. The nanoparticle is coupled with the pharmaceutical ingredient compound through a cross-linking agent, the pharmaceutical ingredient compound is ginsenoside, and the nanoparticle is Au@CoFeB. The invention also discloses the preparation and application of the nanomedicine. The nanomedicine provided by the invention can well inhibit the development of liver cancer, and has both in vitro and in vivo molecular imaging tracing functions. |